Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Sanofi launches voice-guided epinephrine auto-injector in US

Auvi-Q extends pharma company's interests in innovative devices

Sanofi Auvi-Q

Sanofi has launched a voice-guided epinephrine auto-injector Auvi-Q in the US to provide emergency treatment for life-threatening allergic reactions in people who are at risk for, or have a history of, anaphylaxis.

The first-of-its-kind device is the size and shape of a credit card and the thickness of a smart phone. It talks patients and caregivers step-by-step through the injection process. 

Anne Whitaker, president of North America Pharmaceuticals at Sanofi, said: "Patient feedback was a critical component to the development process for Auvi-Q.

"The availability of Auvi-Q represents an important step forward in our continued innovation to meet the needs of people at risk for anaphylaxis and their caregivers."

Up to six million Americans may be at risk for anaphylaxis caused by allergic reactions to the allergens contained in foods like nuts and shellfish, insect stings and certain medications.

For these people epinephrine can play a vital life-saving role, but surveys have found that some two-thirds of patients and caregivers do not carry their epinephrine auto-injectors as recommended.

Moreover, nearly half worry that others will not know how to use their, or their child's, epinephrine auto-injector correctly during an emergency.

Auvi-Q, which will be available through US pharmacies with a prescription from a healthcare provider, provides users with a range of audible and visual cues, including a five-second injection countdown and an alert light to signal when the injection is complete.

The technology underpinning the new device was licensed in November 2009 by Sanofi from Intelliject, which retained commercialisation rights for the product outside the US, and Auvi-Q was approved by the FDA in August last year.

The company will be hoping the launch of Auvi-Q will both boost its position in the allergy market and help its stated aim of becoming “a provider of healthcare solutions”.

Usually for a pharma product the Auvi-Q has won plaudits for its design, and was named at last month's CES Innovations 2013 Design and Engineering Awards as an honoree alongside technologies like Fitbit and Scanadu.

Auvi-Q also adds to a range of innovative devices in Sanofi's key therapy areas that include its iPhone blood glucose meter iBGStar and the AllStar reusable insulin pens for emerging markets.

6th February 2013

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics